Target site modifications and efflux phenotype in clinical isolates of Streptococcus pneumoniae from Hong Kong with reduced susceptibility to fluoroquinolones

被引:16
作者
Ho, PL
Yam, WC
Que, TL
Tsang, DNC
Seto, WH
Ng, TK
Ng, WS
机构
[1] Univ Hong Kong, Dept Microbiol, Div Infect Dis, Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China
[2] Univ Hong Kong, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China
[3] Univ Hong Kong, Sch Profess & Continuing Educ, Hong Kong, Hong Kong, Peoples R China
[4] Tuen Mun Hosp, Dept Clin Pathol, Hong Kong, Hong Kong, Peoples R China
[5] Queen Elizabeth Hosp, Dept Clin Pathol, Hong Kong, Hong Kong, Peoples R China
[6] Princess Margaret Hosp, Dept Clin Pathol, Hong Kong, Hong Kong, Peoples R China
关键词
D O I
10.1093/jac/47.5.655
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Ciprofloxacin-susceptible (n = 7) and -resistant (MIC greater than or equal to 4 mg/L) (n = 15) clinical isolates of Streptococcus pneumoniae from diverse sources in Hong Kong were studied for target site modifications and efflux phenotype, Reserpine-inhibited efflux of ciprofloxacin and/or levofloxacin was common in both susceptible and non-susceptible isolates. The ParC substitutions K137N and/or S79F or Y were associated with increased ciprofloxacin MICs, The GyrA substitution S81F was only found in isolates with full resistance to ciprofloxacin (MIC greater than or equal to 16 mg/L) and levofloxacin (MIC greater than or equal to 8 mg/L). Among clinical isolates of S. pneumoniae, accumulation of target site mutations in strains with an efflux mechanism was associated with increasing MICs of fluoroquinolones.
引用
收藏
页码:655 / 658
页数:4
相关论文
共 9 条
  • [1] Tentative minimum inhibitory concentration and zone diameter breakpoints for moxifloxacin using BSAC criteria
    Andrews, JM
    Ashby, JP
    Jevons, GM
    Wise, R
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (06) : 819 - 822
  • [2] A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus:: Evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux
    Beyer, R
    Pestova, E
    Millichap, JJ
    Stosor, V
    Noskin, GA
    Peterson, LR
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (03) : 798 - 801
  • [3] Efflux and target mutations as quinolone resistance mechanisms in clinical isolates of Streptococcus pneumoniae
    Broskey, J
    Coleman, K
    Gwynn, MN
    McCloskey, L
    Traini, C
    Voelker, L
    Warren, R
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 : 95 - 99
  • [4] Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong
    Ho, PL
    Que, TL
    Tsang, DNC
    Ng, TK
    Chow, KH
    Seto, WH
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (05) : 1310 - 1313
  • [5] High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA
    Janoir, C
    Zeller, V
    Kitzis, MD
    Moreau, NJ
    Gutmann, L
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (12) : 2760 - 2764
  • [6] Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season
    Jones, ME
    Sahm, DF
    Martin, N
    Scheuring, S
    Heisig, P
    Thornsberry, C
    Köhrer, K
    Schmitz, FJ
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (02) : 462 - 466
  • [7] *NCCLS, 1999, PERF STAND ANT SUSC
  • [8] Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae
    Pan, XS
    Ambler, J
    Mehtar, S
    Fisher, LM
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) : 2321 - 2326
  • [9] Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae
    Perichon, B
    Tankovic, J
    Courvalin, P
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (05) : 1166 - 1167